Sickle Cell Disease in Brazil: Current Management

References

• Lippi G, Mattiuzzi C. Updated worldwide epidemiology of inherited erythrocyte disorders. Acta Haematol. 2020;143(3):196–203. doi: 10.1159/000502434.
   PubMed Web of Science ®Google Scholar
• Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585–e599. doi: 10.1016/S2352-3026(23)00118-7.
   PubMed Web of Science ®Google Scholar
• IBGE. | Brasil em síntese | população | taxas brutas de natalidade [Internet]. [cited 2023. Oct 19]. Available from: https://brasilemsintese.ibge.gov.br/populacao/taxas-brutas-de-natalidade.html.
   Google Scholar
• Secretaria de Atenção à Saúde. Departamento de Atenção Especializada.Série B. Textos Básicos de Saúde. Doença Falciforme. Condutas Básicas Para Tratamento. Ministério da Saúde. 2012:9.
   Google Scholar
• Silva WS, de Oliveira RF, Ribeiro SB, et al. Screening for structural hemoglobin variants in Bahia, Brazil. Int J Environ Res Public Health. 2016;13(2):225. doi: 10.3390/ijerph13020225.
   PubMed Web of Science ®Google Scholar
• Indicadores da Triagem Neonatal no Brasil [Internet]. Minist. Saúde. [cited 2023. Nov 14]. Available from: https://www.gov.br/saude/pt-br/composicao/saes/sangue/pntn/indicadores-da-triagem-neonatal/indicadores-da-triagem-neonatal-no-brasil.
   Google Scholar
• Wastnedge E, Waters D, Patel S, et al. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health. 2018;8:021103.
   PubMed Web of Science ®Google Scholar
• Ranque B, Kitenge R, Ndiaye DD, et al. Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study. Lancet Haematol. 2022;9(3):e208–e216. doi: 10.1016/S2352-3026(22)00004-7.
   PubMed Web of Science ®Google Scholar
• Lobo Cl de C, Nascimento Ed, Jesus Ld, et al. Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil. Rev Bras Hematol Hemoter. 2018;40(1):37–42. doi: 10.1016/j.bjhh.2017.09.006.
   PubMedGoogle Scholar
• Cançado RD, Costa FF, Lobo C, et al. Sickle cell disease mortality in Brazil: real-world evidence. Blood. 2021;138(Supplement 1):3025–3025. doi: 10.1182/blood-2021-151098.
   Google Scholar
• Cançado RD, Costa FF, Lobo C, et al. Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence. Blood Adv. 2023;7(15):3783–3792. doi: 10.1182/bloodadvances.2022008938.
   PubMed Web of Science ®Google Scholar
• Cordovil K, Tassinari W, R de Vc de O, et al. Social inequalities in the temporal trend of mortality from sickle cell disease in Brazil, 1996-2019. Cad Saude Publica. 2023;39:e00256421.
   PubMed Web of Science ®Google Scholar
• Mburu J, Odame I. Sickle cell disease: reducing the global disease burden. Int J Lab Hematol. 2019;41 Suppl 1(S1):82–88. doi: 10.1111/ijlh.13023.
   PubMedGoogle Scholar
• Sabarense AP, Lima GO, Silva LML, et al. Characterization of mortality in children with sickle cell disease diagnosed through the Newborn Screening Program. J Pediatr (Rio J). 2015;91(3):242–247. doi: 10.1016/j.jped.2014.08.006.
   PubMed Web of Science ®Google Scholar
• Silva-Pinto AC, Costa FF, Gualandro SFM, et al. Economic burden of sickle cell disease in Brazil. Yassin MA, editor. PLOS One. 2022;17(6):e0269703. doi: 10.1371/journal.pone.0269703.
   PubMed Web of Science ®Google Scholar
• Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol. 2022;15(1):20. doi: 10.1186/s13045-022-01237-z.
   PubMed Web of Science ®Google Scholar
• Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573. doi: 10.1056/NEJMra1510865.
   PubMed Web of Science ®Google Scholar
• Jang T, Poplawska M, Cimpeanu E, et al. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med. 2021;19(1):397. doi: 10.1186/s12967-021-03074-z.
   PubMed Web of Science ®Google Scholar
• Conran N, Embury SH. Sickle cell vaso-occlusion: the dialectic between red cells and white cells. Exp Biol Med (Maywood). 2021;246(12):1458–1472. doi: 10.1177/15353702211005392.
   PubMed Web of Science ®Google Scholar
• Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14(1):263–292. doi: 10.1146/annurev-pathmechdis-012418-012838.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primer. 2018;4:18010.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647–3656. doi: 10.1182/blood-2012-04-383430.
   PubMed Web of Science ®Google Scholar
• Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease – life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644. doi: 10.1056/NEJM199406093302303.
   PubMed Web of Science ®Google Scholar
• Ware RE, de Montalembert M, Tshilolo L, et al. Sickle cell disease. Lancet. 2017;390(10091):311–323. doi: 10.1016/S0140-6736(17)30193-9.
   PubMed Web of Science ®Google Scholar
• Pinto VM, Balocco M, Quintino S, et al. Sickle cell disease: a review for the internist. Intern Emerg Med. 2019;14(7):1051–1064. doi: 10.1007/s11739-019-02160-x.
   PubMed Web of Science ®Google Scholar
• Thein SL. Genetic basis and genetic modifiers of β-thalassemia and sickle cell disease. In: Malik P, Tisdale J, editors. Gene cell ther beta-globinopathies [Internet]. New York, NY: Springer; 2017. p. 27–57. [cited 2023 Nov 1]. Available from: doi: 10.1007/978-1-4939-7299-9_2.
   Google Scholar
• Fertrin KY, Costa FF. Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment. Expert Rev Hematol. 2010;3(4):443–458. doi: 10.1586/ehm.10.44.
   PubMed Web of Science ®Google Scholar
• Serjeant GR, Vichinsky E. Variability of homozygous sickle cell disease: the role of alpha and beta globin chain variation and other factors. Blood Cells Mol Dis. 2018;70:66–77. doi: 10.1016/j.bcmd.2017.06.004.
   PubMed Web of Science ®Google Scholar
• Carneiro-Proietti ABF, Kelly S, Teixeira CM, et al. Clinical and genetic ancestry profile of a large multi-centre sickle cell disease cohort in Brazil. Br J Haematol. 2018;182(6):895–908. doi: 10.1111/bjh.15462.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37–47. doi: 10.1016/j.blre.2006.07.001.
   PubMed Web of Science ®Google Scholar
• The lancet haematology commission on sickle cell disease: key recommendations. Lancet Haematol. 2023;10:e564–e567.
   PubMed Web of Science ®Google Scholar
• Esoh K, Wonkam A. Evolutionary history of sickle-cell mutation: implications for global genetic medicine. Hum Mol Genet. 2021;30(R1):R119–R128. doi: 10.1093/hmg/ddab004.
   PubMed Web of Science ®Google Scholar
• Olupot-Olupot P, Tomlinson G, Williams TN, et al. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood. 2023;141(12):1402–1410. doi: 10.1182/blood.2022017051.
   PubMed Web of Science ®Google Scholar
• Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2019;380(2):121–131. doi: 10.1056/NEJMoa1813598.
   PubMed Web of Science ®Google Scholar
• Situação epidemiológica da malária na região amazônica e extra-amazônica. a abril de 2023. Dados atualizados em: Sivep-Malária em 27/12/2023; Sinan em 10/12/2023;E-SUS-VS em 13/11/2023. *Dados de 2023 são sujeitos à alteração. [Internet]. Tableau Softw, 2007. [cited 2024 Feb 4]. Available from: https://public.tableau.com/views/BoletimMalrianasregiesamaznicaeextra-amaznica/Incio?%3Adisplay_static_image=y&%3AbootstrapWhenNotified=true&%3Aembed=true&%3Alanguage=en-US&:embed=y&:showVizHome=n&:apiID=host0#navType=0&navSrc=Parse.
   Google Scholar
• Secretaria de Vigilância em Saúde, Departamento de Imunização e Doenças Transmissíveis. Brasília: Ministério da Saúde. Guia de tratamento da malária no Brasil [recurso eletrônico]. 2020. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/guia_tratamento_malaria_brasil.pdf.
   Google Scholar
• CONITEC. Protocolo clínico e diretrizes terapêuticas da doença falciforme. Portaria Conjunta No 05, DE 19 DE FEVEREIRO DE 2018. Minist Saúde [Internet]. 2018. Available from: http://conitec.gov.br/images/Protocolos/PCDT_DoencaFalciforme_2018.pdf.
   Google Scholar
• Hoppe C, Neumayr L. Sickle cell disease: monitoring, current treatment, and therapeutics under development. Hematol Oncol Clin North Am. 2019;33(3):355–371. doi: 10.1016/j.hoc.2019.01.014.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Darbari DS. Review/overview of pain in sickle cell disease. Complement Ther Med. 2020;49:102327. doi: 10.1016/j.ctim.2020.102327.
   PubMed Web of Science ®Google Scholar
• Cançado RD. Sickle cell disease: looking back but towards the future. Rev Bras Hematol Hemoter. 2012;34(3):175–177. doi: 10.5581/1516-8484.20120041.
   PubMedGoogle Scholar
• Pleasants S. Epidemiology: a moving target. Nature. 2014;515(7526):S2–S3. doi: 10.1038/515S2a.
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep. 2013;128(2):110–116. doi: 10.1177/003335491312800206.
   PubMed Web of Science ®Google Scholar
• Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA. 2022;328(1):57–68. doi: 10.1001/jama.2022.10233.
   PubMed Web of Science ®Google Scholar
• Ballas SK. Sickle cell disease: Classification of clinical complications and approaches to preventive and therapeutic management. Clin Hemorheol Microcirc. 2018;68(2–3):105–128. doi: 10.3233/CH-189002.
   Google Scholar
• Sagi V, Mittal A, Tran H, et al. Pain in sickle cell disease: current and potential translational therapies. Transl Res. 2021;234:141–158. doi: 10.1016/j.trsl.2021.03.007.
   PubMed Web of Science ®Google Scholar
• Lobo C, Marra VN, Silva RMG. Crises dolorosas na doença falciforme. Rev Bras Hematol E Hemoter. 2007;29:247–258.
   Google Scholar
• Yang J, Bauer BA, Wahner-Roedler DL, et al. The modified WHO analgesic ladder: is it appropriate for chronic non-cancer pain? J Pain Res. 2020;13:411–417. doi: 10.2147/JPR.S244173.
   PubMed Web of Science ®Google Scholar
• Ruta NS, Ballas SK. The opioid drug epidemic and sickle cell disease: guilt by association. Pain Med. 2016;17(10):1793–1798. doi: 10.1093/pm/pnw074.
   PubMed Web of Science ®Google Scholar
• Sagi V, Argueta DA, Kiven S, et al. Integrative approaches to treating pain in sickle cell disease: pre-clinical and clinical evidence. Complement Ther Med. 2020;51:102394. doi: 10.1016/j.ctim.2020.102394.
   PubMed Web of Science ®Google Scholar
• Campos J, Lobo C, Queiroz AMM, et al. Treatment of the acute sickle cell vaso-occlusive crisis in the emergency department: a Brazilian method of switching from intravenous to oral morphine. Eur J Haematol. 2014;93(1):34–40. doi: 10.1111/ejh.12293.
   PubMed Web of Science ®Google Scholar
• Braga JAP, Veríssimo MPdA, Saad STO, et al. Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: associação Médica Brasileira – 2016. Rev Bras Hematol Hemoter. 2016;38(2):147–157. doi: 10.1016/j.bjhh.2016.04.001.
   PubMedGoogle Scholar
• Piccin A, Murphy C, Eakins E, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Eur J Haematol. 2019;102(4):319–330. doi: 10.1111/ejh.13212.
   PubMed Web of Science ®Google Scholar
• Lettre G, Bauer DE. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. Lancet. 2016;387(10037):2554–2564. doi: 10.1016/S0140-6736(15)01341-0.
   PubMed Web of Science ®Google Scholar
• Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018;68(2–3):263–299. doi: 10.3233/CH-189012.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. doi: 10.1056/NEJM199505183322001.
   PubMed Web of Science ®Google Scholar
• Wang WC, Ware RE, Miller ST, et al. A multicenter randomised controlled trial of hydroxyurea (hydroxycarbamide) in very young children with sickle cell anaemia. Lancet. 2011;377(9778):1663–1672. doi: 10.1016/S0140-6736(11)60355-3.
   PubMed Web of Science ®Google Scholar
• Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer. 2012;59(2):386–390. doi: 10.1002/pbc.24175.
   PubMed Web of Science ®Google Scholar
• Meier ER. Treatment options for sickle cell disease. Pediatr Clin North Am. 2018;65(3):427–443. doi: 10.1016/j.pcl.2018.01.005.
   PubMed Web of Science ®Google Scholar
• Ware RE, Dertinger SD. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. Br J Haematol. 2021;194(2):252–266. doi: 10.1111/bjh.17323.
   PubMed Web of Science ®Google Scholar
• CONITEC. Protocolo Clínico e Diretrizes Terapêuticas Doença Falciforme. Relatório de recomendação [Internet]. Ministério da Saúde; 2016. Available from: http://conitec.gov.br/images/Consultas/Relatorios/2016/Relatorio_PCDT_DoencaFalciforme_CP_2016_v2.pdf.
   Google Scholar
• Power-Hays A, Ware RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Curr Opin Hematol. 2020;27(3):172–180. doi: 10.1097/MOH.0000000000000582.
   PubMed Web of Science ®Google Scholar
• Dong M, McGann PT. Changing the clinical paradigm of hydroxyurea treatment for sickle cell anemia through precision medicine. Clin Pharmacol Ther. 2021;109(1):73–81. doi: 10.1002/cpt.2028.
   PubMed Web of Science ®Google Scholar
• Sales RR, Nogueira BL, Tosatti JAG, et al. Do genetic polymorphisms affect fetal hemoglobin (HbF) levels in patients with sickle cell anemia treated with hydroxyurea? A systematic review and pathway analysis. Front Pharmacol. 2021;12:779497. doi: 10.3389/fphar.2021.779497.
   PubMed Web of Science ®Google Scholar
• Vick L, Potts M, Jaskowiak M, et al. Hydroxyurea adherence strategies for persons with sickle cell disease: a systematic review. J Health Care Poor Underserved. 2021;32(1):99–118. doi: 10.1353/hpu.2021.0011.
   PubMed Web of Science ®Google Scholar
• Ware RE. Optimizing hydroxyurea therapy for sickle cell anemia. Hematology Am Soc Hematol Educ Program. 2015;2015:436–443. doi: 10.1182/asheducation-2015.1.436.
   Google Scholar
• de Montalembert M, Voskaridou E, Oevermann L, et al. Real-life experience with hydroxyurea in patients with sickle cell disease: results from the prospective ESCORT-HU cohort study. Am J Hematol. 2021;96(10):1223–1231. doi: 10.1002/ajh.26286.
   PubMed Web of Science ®Google Scholar
• Oteng-Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood. 2015;125(21):3316–3325. doi: 10.1182/blood-2014-11-607317.
   PubMed Web of Science ®Google Scholar
• Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2009;2009(1):62–69. doi: 10.1182/asheducation-2009.1.62.
   Google Scholar
• McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–1758. doi: 10.1517/14740338.2015.1088827.
   PubMed Web of Science ®Google Scholar
• Kirkham FJ, Lagunju IA. Epidemiology of stroke in sickle cell disease. J Clin Med. 2021;10(18):4232. doi: 10.3390/jcm10184232.
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, randomised controlled trial. Lancet. 2016;387(10019):661–670. doi: 10.1016/S0140-6736(15)01041-7.
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med. 1998;339(1):5–11. doi: 10.1056/NEJM199807023390102.
   PubMed Web of Science ®Google Scholar
• The optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–2778.
   PubMed Web of Science ®Google Scholar
• Ware RE, Helms RW, SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925–3932. doi: 10.1182/blood-2011-11-392340.
   PubMed Web of Science ®Google Scholar
• Loggetto SR, Veríssimo MPdA, Darrigo-Junior LG, et al. Guidelines on sickle cell disease: primary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines project: associação Médica Brasileira - 2021. Hematol Transfus Cell Ther. 2022;44(1):85–94. doi: 10.1016/j.htct.2021.09.013.
   PubMedGoogle Scholar
• Góis CRTd, D'Ávila JS, Cipolotti R, et al. Adenotonsillar hypertrophy in pre-school children with sickle cell disease and diagnostic accuracy of the sleep disturbance scale for children. Int Arch Otorhinolaryngol. 2018;22(1):55–59. doi: 10.1055/s-0037-1602702.
   PubMedGoogle Scholar
• Salles C, Ramos RTT, Daltro C, et al. Association between adenotonsillar hypertrophy, tonsillitis and painful crises in sickle cell disease. J Pediatr (Rio J). 2009;85(3):249–253. doi: 10.2223/JPED.1898.
   PubMed Web of Science ®Google Scholar
• Abou-Elhamd K-EA. Otorhinolaryngological manifestations of sickle cell disease. Int J Pediatr Otorhinolaryngol. 2012;76(1):1–4. doi: 10.1016/j.ijporl.2011.10.004.
   PubMed Web of Science ®Google Scholar
• Salles C, Ramos RTT, Daltro C, et al. Prevalence of obstructive sleep apnea in children and adolescents with sickle cell anemia. J Bras Pneumol Publicacao of Soc Bras Pneumol E Tisilogia. 2009;35:1075–1083.
   PubMed Web of Science ®Google Scholar
• Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130(3):576–584. doi: 10.1542/peds.2012-1671.
   PubMed Web of Science ®Google Scholar
• Grady AJ, Hankins JS, Haberman B, et al. Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea. Sleep Breath. 2017;21(3):697–701. doi: 10.1007/s11325-017-1458-9.
   PubMed Web of Science ®Google Scholar
• Narang I, Kadmon G, Lai D, et al. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy. Ann Am Thorac Soc. 2015;12(7):1044–1049. doi: 10.1513/AnnalsATS.201410-473OC.
   PubMed Web of Science ®Google Scholar
• Suddle AR. Management of liver complications in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2019;2019(1):345–350. doi: 10.1182/hematology.2019000037.
   PubMedGoogle Scholar
• Kyrana E, Rees D, Lacaille F, et al. Clinical management of sickle cell liver disease in children and young adults. Arch Dis Child. 2021;106(4):315–320. doi: 10.1136/archdischild-2020-319778.
   PubMed Web of Science ®Google Scholar
• Praharaj DL, Anand AC. Sickle hepatopathy. J Clin Exp Hepatol. 2021;11(1):82–96. doi: 10.1016/j.jceh.2020.08.003.
   PubMed Web of Science ®Google Scholar
• Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013;88(11):932–938. doi: 10.1002/ajh.23547.
   PubMed Web of Science ®Google Scholar
• Azbell RCG, Desai PC. Treatment dilemmas: strategies for priapism, chronic leg ulcer disease, and pulmonary hypertension in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2021;2021(1):411–417. doi: 10.1182/hematology.2021000275.
   PubMedGoogle Scholar
• Reis de Souza V, Kelly S, Cerdeira Sabino E, et al. Factors associated with leg ulcers in adults with sickle cell disease in Brazil. Adv Skin Wound Care. 2023;36(2):98–105. doi: 10.1097/01.ASW.0000911152.41719.e5.
   PubMed Web of Science ®Google Scholar
• Martí-Carvajal AJ, Knight-Madden JM, Martinez-Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database Syst Rev. 2021;1(1):CD008394. doi: 10.1002/14651858.CD008394.pub4.
   PubMedGoogle Scholar
• Tolu SS, Crouch A, Choi J, et al. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease. Ann Hematol. 2022;101(3):541–548. doi: 10.1007/s00277-021-04635-4.
   PubMed Web of Science ®Google Scholar
• de Carvalho-Siqueira GQ, Ananina G, de Souza BB, et al. Highlight article: whole-exome sequencing indicates FLG2 variant associated with leg ulcers in Brazilian sickle cell anemia patients. Exp Biol Med (Maywood). 2019;244(11):932–939. doi: 10.1177/1535370219849592.
   PubMed Web of Science ®Google Scholar
• Benites B, Guidini V, Lino J, et al. Hidroxiureia E Úlceras de Membros: Vale A Pena suspender? Estudo de Coorte Retrospectivo de Pacientes Adultos Brasileiros com Doença Falciforme. Hematol Transfus Cell Ther. 2022;44:S54–S55. doi: 10.1016/j.htct.2022.09.091.
   Google Scholar
• Queiroz AMM, Campos J, Lobo C, et al. Leg amputation for an extensive, severe and intractable sickle cell anemia ulcer in a Brazilian patient. Hemoglobin. 2014;38(2):95–98. doi: 10.3109/03630269.2013.875476.
   PubMed Web of Science ®Google Scholar
• Maximo C, Olalla Saad ST, Thome E, et al. Amputations in sickle cell disease: case series and literature review. Hemoglobin. 2016;40(3):150–155. doi: 10.3109/03630269.2016.1167736.
   PubMed Web of Science ®Google Scholar
• Monfort J-B, Senet P. Leg ulcers in sickle-cell disease: treatment update. Adv Wound Care (New Rochelle). 2020;9(6):348–356. doi: 10.1089/wound.2018.0918.
   PubMed Web of Science ®Google Scholar
• Adebayo OC, Van den Heuvel LP, Olowu WA, et al. Sickle cell nephropathy: insights into the pediatric population. Pediatr Nephrol. 2021;37(6):1231–1243. [cited 2022 Mar 23]; Available from: doi: 10.1007/s00467-021-05126-4.
   PubMed Web of Science ®Google Scholar
• Roy NB, Fortin PM, Bull KR, et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev. 2017;2017:CD012380.
   Google Scholar
• Belisário AR, Simões e Silva AC, Moura ICG, et al. Estimated glomerular filtration rate in Brazilian adults with sickle cell disease: results from the REDS-III multicenter cohort study. Ann Hematol. 2023;102(5):1019–1027. doi: 10.1007/s00277-023-05150-4.
   PubMed Web of Science ®Google Scholar
• Alvarez O, Miller ST, Wang WC, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer. 2012;59(4):668–674. doi: 10.1002/pbc.24100.
   PubMed Web of Science ®Google Scholar
• Steinberg M, McCarthy W, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408. doi: 10.1002/ajh.21699.
   PubMed Web of Science ®Google Scholar
• Musicki B, Burnett AL. Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape. Expert Opin Ther Targets. 2020;24(5):439–450. doi: 10.1080/14728222.2020.1745188.
   PubMed Web of Science ®Google Scholar
• Ahuja G, Ibecheozor C, Okorie NC, et al. Priapism and sickle cell disease: special considerations in etiology, management, and prevention. Urology. 2021;156:e40–e47. doi: 10.1016/j.urology.2021.06.010.
   PubMed Web of Science ®Google Scholar
• Joice GA, Liu JL, Burnett AL. Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm. BJU Int. 2021;127(5):498–506. doi: 10.1111/bju.15370.
   PubMed Web of Science ®Google Scholar
• Olujohungbe A, Burnett AL. How I manage priapism due to sickle cell disease. Br J Haematol. 2013;160(6):754–765. doi: 10.1111/bjh.12199.
   PubMed Web of Science ®Google Scholar
• Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2020;4(4):CD004198. doi: 10.1002/14651858.CD004198.pub4.
   PubMedGoogle Scholar
• Saad STO, Lajolo C, Gilli S, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77(1):45–49. doi: 10.1002/ajh.20142.
   PubMed Web of Science ®Google Scholar
• Gbotosho OT, Taylor M, Malik P. Cardiac pathophysiology in sickle cell disease. J Thromb Thrombolysis. 2021;52(1):248–259. doi: 10.1007/s11239-021-02414-6.
   PubMed Web of Science ®Google Scholar
• Gupta A, Fei Y-D, Kim TY, et al. IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias. Blood. 2021;137(9):1208–1218. doi: 10.1182/blood.2020005944.
   PubMed Web of Science ®Google Scholar
• Sasongko TH, Nagalla S. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database Syst Rev. 2021;12(12):CD009191. doi: 10.1002/14651858.CD009191.pub4.
   PubMedGoogle Scholar
• Foucan L, Bourhis V, Bangou J, et al. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med. 1998;104(4):339–342. doi: 10.1016/s0002-9343(98)00056-4.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Saraf SL, Derebail VK. The nephropathy of sickle cell trait and sickle cell disease. Nat Rev Nephrol. 2022;18(6):361–377. [cited 2022 Mar 23]; Available from: https://www.nature.com/articles/s41581-022-00540-9.
   PubMed Web of Science ®Google Scholar
• Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96(12B):29M–31M. doi: 10.1016/j.amjcard.2005.07.008.
   PubMed Web of Science ®Google Scholar
• Burnett AL, Bivalacqua TJ, Champion HC, et al. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3(6):1077–1084. doi: 10.1111/j.1743-6109.2006.00333.x.
   PubMed Web of Science ®Google Scholar
• Nardozza A, Cabrini MR. Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism. Rev Assoc Med Bras (1992). 2017;63(8):689–692. doi: 10.1590/1806-9282.63.08.689.
   PubMed Web of Science ®Google Scholar
• Hou LT, Burnett AL. Regimented phosphodiesterase type 5 inhibitor use reduces emergency department visits for recurrent ischemic priapism. J Urol. 2021;205(2):545–553. doi: 10.1097/JU.0000000000001365.
   PubMedGoogle Scholar
• Fibach E, Rachmilewitz EA. Does erythropoietin have a role in the treatment of β-hemoglobinopathies? Hematol Oncol Clin North Am. 2014;28(2):249–263. doi: 10.1016/j.hoc.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Pulte ED, McKenzie SE, Caro J, et al. Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin. Hemoglobin. 2014;38(6):385–389. doi: 10.3109/03630269.2014.967868.
   PubMed Web of Science ®Google Scholar
• Pulte D, Nagalla S, Caro J. Erythropoietin levels in patients with sickle cell disease not in vaso-occlusive crisis. Blood. 2012;120(21):3242–3242. doi: 10.1182/blood.V120.21.3242.3242.
   Google Scholar
• Steinberg M. Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med. 1991;324(19):1369–1370. doi: 10.1056/NEJM199105093241916.
   PubMed Web of Science ®Google Scholar
• Han J, Zhou J, Kondragunta V, et al. Erythropoiesis-stimulating agents in sickle cell anaemia. Br J Haematol. 2018;182(4):602–605. doi: 10.1111/bjh.14846.
   PubMed Web of Science ®Google Scholar
• Ferreira FA, Benites BD, Costa FF, et al. Recombinant erythropoietin as alternative to red cell transfusion in sickle cell disease. Vox Sang. 2019;114(2):178–181. doi: 10.1111/vox.12750.
   PubMed Web of Science ®Google Scholar
• Abboud MR. Standard management of sickle cell disease complications. Hematol Oncol Stem Cell Ther. 2020;13(2):85–90. doi: 10.1016/j.hemonc.2019.12.007.
   PubMedGoogle Scholar
• Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematol Oncol Clin North Am. 2016;30(3):591–608. doi: 10.1016/j.hoc.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Pirenne F, Floch A, Habibi A. How to avoid the problem of erythrocyte alloimmunization in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2021;2021(1):689–695. doi: 10.1182/hematology.2021000306.
   PubMedGoogle Scholar
• Pirenne F, Bartolucci P, Habibi A. Management of delayed hemolytic transfusion reaction in sickle cell disease: prevention, diagnosis, treatment. Transfus Clin Biol. 2017;24(3):227–231. doi: 10.1016/j.tracli.2017.05.016.
   PubMed Web of Science ®Google Scholar
• Theocharidou E, Suddle AR. The liver in sickle cell disease. Clin Liver Dis. 2019;23(2):177–189. doi: 10.1016/j.cld.2018.12.002.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Chou ST. Transfusion and cellular therapy in pediatric sickle cell disease. Clin Lab Med. 2021;41(1):101–119. doi: 10.1016/j.cll.2020.10.007.
   PubMed Web of Science ®Google Scholar
• Lobo Cl de C, Cançado RD, Leite ACCB, et al. Brazilian Guidelines for transcranial doppler in children and adolescents with sickle cell disease. Rev Bras Hematol Hemoter. 2011;33(1):43–48. doi: 10.5581/1516-8484.20110014.
   PubMedGoogle Scholar
• Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol. 2005;84(7):434–440. doi: 10.1007/s00277-005-1015-7.
   PubMed Web of Science ®Google Scholar
• Nacional I. PORTARIA No 298, DE 9 DE FEVEREIRO DE 2018 - Imprensa Nacional [Internet]. Available from: https://www.in.gov.br/materia.
   Google Scholar
• Badawy SM, Beg U, Liem RI, et al. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Adv. 2021;5(2):570–583. doi: 10.1182/bloodadvances.2020002948.
   PubMed Web of Science ®Google Scholar
• Iqbal M, Reljic T, Corbacioglu S, et al. Systematic review/meta-analysis on efficacy of allogeneic hematopoietic cell transplantation in sickle cell disease: An international effort on behalf of the pediatric diseases working party of european society for blood and marrow transplantation and the sickle cell transplantation international consortium. Transplant Cell Ther. 2021;27(2):167.e1–167.e12. doi: 10.1016/j.jtct.2020.10.007.
   PubMedGoogle Scholar
• Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548–1556. doi: 10.1182/blood-2016-10-745711.
   PubMed Web of Science ®Google Scholar
• Costa TCdM, Chiari-Correia R, Salmon CEG, et al. Hematopoietic stem cell transplantation reverses white matter injury measured by diffusion-tensor imaging (DTI) in sickle cell disease patients. Bone Marrow Transplant. 2021;56(11):2705–2713. doi: 10.1038/s41409-021-01365-z.
   PubMed Web of Science ®Google Scholar
• de Azevedo JTC, Costa Tc de M, Lima KC, et al. Long-term effects of allogeneic hematopoietic stem cell transplantation on systemic inflammation in sickle cell disease patients. Front Immunol. 2021;12:774442. doi: 10.3389/fimmu.2021.774442.
   PubMedGoogle Scholar
• Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database Syst Rev. 2020;7(7):CD007001. doi: 10.1002/14651858.CD007001.pub5.
   PubMedGoogle Scholar
• Oevermann L, Sodani P. Status quo of allogeneic stem cell transplantation for patients with sickle cell disease using matched unrelated donors. Hematol Oncol Stem Cell Ther. 2020;13(2):116–119. doi: 10.1016/j.hemonc.2019.12.004.
   PubMedGoogle Scholar
• Patel DA, Akinsete AM, de la Fuente J, et al. Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update. Hematol Oncol Stem Cell Ther. 2020;13(2):91–97. doi: 10.1016/j.hemonc.2020.01.002.
   PubMedGoogle Scholar
• Foell J, Schulte JH, Pfirstinger B, et al. Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transplant. 2019;54(11):1859–1867. doi: 10.1038/s41409-019-0550-0.
   PubMed Web of Science ®Google Scholar
• Foell J, Kleinschmidt K, Jakob M, et al. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease. Hematol Oncol Stem Cell Ther. 2020;13(2):98–105. doi: 10.1016/j.hemonc.2019.12.006.
   PubMedGoogle Scholar
• Shah F, Dwivedi M. Pathophysiology and recent therapeutic insights of sickle cell disease. Ann Hematol. 2020;99(5):925–935. doi: 10.1007/s00277-020-03977-9.
   PubMed Web of Science ®Google Scholar
• Monus T, Howell CM. Current and emerging treatments for sickle cell disease. JAAPA. 2019;32(9):1–5. doi: 10.1097/01.JAA.0000578812.47138.99.
   PubMedGoogle Scholar
• Pace BS, Starlard-Davenport A, Kutlar A. Sickle cell disease: progress towards combination drug therapy. Br J Haematol. 2021;194(2):240–251. doi: 10.1111/bjh.17312.
   PubMed Web of Science ®Google Scholar
• Araújo AdS, Silva Pinto AC, Lobo CdC, et al. Novel insights into the pathophysiology and treatment of sickle cell disease. Hemoglobin. 2023;47(2):71–79. doi: 10.1080/03630269.2023.2211771.
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Makani J. Hydroxyurea—an essential medicine for sickle cell disease in Africa. N Engl J Med. 2019;380(2):187–189. doi: 10.1056/NEJMe1814706.
   PubMed Web of Science ®Google Scholar
• Stettler N, McKiernan CM, Melin CQ, et al. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA. 2015;313(16):1671–1672. doi: 10.1001/jama.2015.3075.
   PubMed Web of Science ®Google Scholar
• Yesilipek MA. Hematopoietic stem cell transplantation in patients with hemoglobinopathies. Hemoglobin. 2020;44(6):377–384. doi: 10.1080/03630269.2020.1832516.
   PubMed Web of Science ®Google Scholar
• Leonard A, Tisdale J, Abraham A. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? Br J Haematol. 2020;189(3):408–423. doi: 10.1111/bjh.16437.
   PubMed Web of Science ®Google Scholar
• Carden MA, Little J. Emerging disease-modifying therapies for sickle cell disease. Haematologica. 2019;104(9):1710–1719. doi: 10.3324/haematol.2018.207357.
   PubMed Web of Science ®Google Scholar